2025 Q4 -tulosraportti
25 päivää sitten
‧49 min
8,00 NOK/osake
Irtoamispäivä 7.5.
2,79%Tuotto/v
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 27.2. | ||
2025 Q3 -tulosraportti 24.10.2025 | ||
2025 Q2 -tulosraportti 20.8.2025 | ||
2025 Q1 -tulosraportti 9.5.2025 | ||
2024 Q4 -tulosraportti 28.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·3 päivää sittenHave started looking a bit at Medistim and think it seems like a solid niche case with high quality, especially regarding margins and recurring revenues. At the same time, I'm left with the question of how much of this is already priced in. How do you view further growth, especially internationally, and any potential triggers going forward?
·2 päivää sittenMedistim is still valued as a quality company, but the premium is not particularly high from a historical perspective. In my assessment, the valuation was more demanding in the period 2021 - 2023, while today's valuation is much more attractive. At a price around 215, you buy the share at approx. P/E 24.7, against historical averages of approximately 29.9 (3 years), 37.4 (5 years) and 37.5 (10 years). For that price, you get a company with: Gross margin: ~81.7% EBIT margin: ~28.0% Profit margin: ~22.8% FCF margin: ~22.2% ROE: ~34% ROIC: ~52% In addition, the company has a net cash position, good liquidity and a high equity ratio. Companies that consistently deliver these types of margins and capital returns are often valued at a premium. If Medistim continues to deliver at the same level regarding growth and profitability, the share can function well as a long-term compounder. And then one can speculate on what happens if they deliver even better, are acquired, or other triggering factors. But remember that the market knows this, so this is unfortunately no hidden gem. What can count positively is that the liquidity in the share is low and therefore prevents large players from actively trading it, as it takes time to get in and out with large positions. In my eyes, this can be a big and underestimated advantage if you are not going in and out with many millions every time. So then it's up to you to assess whether the company can continue to deliver and thus deserve the price you might be willing to pay for their cash flows.
18.3.18.3.Intertrade Shipping AS, which is partly owned and controlled by Øyvin A. Brøymer, has today purchased 50,000 shares in Medistim ASA at NOK 208 per share, - totaling NOK 10,400,000. Øyvin A. Brøymer is the chairman of the board in Medistim ASA. After the purchase, Intertrade Shipping AS owns 1,015,001 shares in the company. Fløtemarken AS, which is a 100% owned company of Intertrade Shipping AS, additionally owns 1,285,000 shares in Medistim ASA. In total, Øyvin A. Brøymer controls 2,300,001 shares in Medistim ASA after the purchased.
13.3.13.3.MEDI: Intertrade Shipping AS purchases Medistim shares Close i dag kl. 14:14 ∙ Oslo Børs Medistim Intertrade Shipping AS, which is partly-owned and controlled by Øyvin A. Brøymer, has today purchased 29,266 shares in Medistim ASA at NOK 200.5776 per share, - totaling NOK 5,875,974.14. Øyvin A. Brøymer is the chairman of the board in Medistim ASA. After the purchase, Intertrade Shipping AS owns 965,001 shares in the company. Fløtemarken AS, which is a 100% owned company of Intertrade Shipping AS, additionally owns 1,285,000 shares in Medistim ASA. In total, Øyvin A. Brøymer controls 2,250,001 shares in Medistim ASA after the purchase.
·13.3.I would like to know the reason for selling below 200 kr from some of those who are doing it now, after the company delivered stellar figures in Q4, a record year last year, and the highest dividend to date. I would appreciate hearing the reason for that, unless it's personal reasons, of course.- ·12.3.This stock seems to be a somewhat forgotten stock. Very rarely mentioned in the financial press, and very little commented on in forums. This gem has been on the stock exchange for a long time, delivers good results with a record in Q4 and for the full year 2025. Quite decent dividend (8 kr /approx 4%) and an attractive portfolio of own products for hospitals and healthcare enterprises. This is not something AI can destroy, and this is also not a market that will cease to exist; on the contrary, healthcare will likely only grow due to an aging population. After the Q4 figures, it rose so much that I was tempted to sell out at 230, but have now bought back my shares again, at a price I find very favorable. No reason for Medistim to fall as it has done after the figures other than that it is an unsettled market. If one is long-term, one sits well in this fine stock, in my opinion.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
25 päivää sitten
‧49 min
8,00 NOK/osake
Irtoamispäivä 7.5.
2,79%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 päivää sittenHave started looking a bit at Medistim and think it seems like a solid niche case with high quality, especially regarding margins and recurring revenues. At the same time, I'm left with the question of how much of this is already priced in. How do you view further growth, especially internationally, and any potential triggers going forward?·2 päivää sittenMedistim is still valued as a quality company, but the premium is not particularly high from a historical perspective. In my assessment, the valuation was more demanding in the period 2021 - 2023, while today's valuation is much more attractive. At a price around 215, you buy the share at approx. P/E 24.7, against historical averages of approximately 29.9 (3 years), 37.4 (5 years) and 37.5 (10 years). For that price, you get a company with: Gross margin: ~81.7% EBIT margin: ~28.0% Profit margin: ~22.8% FCF margin: ~22.2% ROE: ~34% ROIC: ~52% In addition, the company has a net cash position, good liquidity and a high equity ratio. Companies that consistently deliver these types of margins and capital returns are often valued at a premium. If Medistim continues to deliver at the same level regarding growth and profitability, the share can function well as a long-term compounder. And then one can speculate on what happens if they deliver even better, are acquired, or other triggering factors. But remember that the market knows this, so this is unfortunately no hidden gem. What can count positively is that the liquidity in the share is low and therefore prevents large players from actively trading it, as it takes time to get in and out with large positions. In my eyes, this can be a big and underestimated advantage if you are not going in and out with many millions every time. So then it's up to you to assess whether the company can continue to deliver and thus deserve the price you might be willing to pay for their cash flows.
- 18.3.18.3.Intertrade Shipping AS, which is partly owned and controlled by Øyvin A. Brøymer, has today purchased 50,000 shares in Medistim ASA at NOK 208 per share, - totaling NOK 10,400,000. Øyvin A. Brøymer is the chairman of the board in Medistim ASA. After the purchase, Intertrade Shipping AS owns 1,015,001 shares in the company. Fløtemarken AS, which is a 100% owned company of Intertrade Shipping AS, additionally owns 1,285,000 shares in Medistim ASA. In total, Øyvin A. Brøymer controls 2,300,001 shares in Medistim ASA after the purchased.
- 13.3.13.3.MEDI: Intertrade Shipping AS purchases Medistim shares Close i dag kl. 14:14 ∙ Oslo Børs Medistim Intertrade Shipping AS, which is partly-owned and controlled by Øyvin A. Brøymer, has today purchased 29,266 shares in Medistim ASA at NOK 200.5776 per share, - totaling NOK 5,875,974.14. Øyvin A. Brøymer is the chairman of the board in Medistim ASA. After the purchase, Intertrade Shipping AS owns 965,001 shares in the company. Fløtemarken AS, which is a 100% owned company of Intertrade Shipping AS, additionally owns 1,285,000 shares in Medistim ASA. In total, Øyvin A. Brøymer controls 2,250,001 shares in Medistim ASA after the purchase.
- ·13.3.I would like to know the reason for selling below 200 kr from some of those who are doing it now, after the company delivered stellar figures in Q4, a record year last year, and the highest dividend to date. I would appreciate hearing the reason for that, unless it's personal reasons, of course.
- ·12.3.This stock seems to be a somewhat forgotten stock. Very rarely mentioned in the financial press, and very little commented on in forums. This gem has been on the stock exchange for a long time, delivers good results with a record in Q4 and for the full year 2025. Quite decent dividend (8 kr /approx 4%) and an attractive portfolio of own products for hospitals and healthcare enterprises. This is not something AI can destroy, and this is also not a market that will cease to exist; on the contrary, healthcare will likely only grow due to an aging population. After the Q4 figures, it rose so much that I was tempted to sell out at 230, but have now bought back my shares again, at a price I find very favorable. No reason for Medistim to fall as it has done after the figures other than that it is an unsettled market. If one is long-term, one sits well in this fine stock, in my opinion.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 27.2. | ||
2025 Q3 -tulosraportti 24.10.2025 | ||
2025 Q2 -tulosraportti 20.8.2025 | ||
2025 Q1 -tulosraportti 9.5.2025 | ||
2024 Q4 -tulosraportti 28.2.2025 |
2025 Q4 -tulosraportti
25 päivää sitten
‧49 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 27.2. | ||
2025 Q3 -tulosraportti 24.10.2025 | ||
2025 Q2 -tulosraportti 20.8.2025 | ||
2025 Q1 -tulosraportti 9.5.2025 | ||
2024 Q4 -tulosraportti 28.2.2025 |
8,00 NOK/osake
Irtoamispäivä 7.5.
2,79%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 päivää sittenHave started looking a bit at Medistim and think it seems like a solid niche case with high quality, especially regarding margins and recurring revenues. At the same time, I'm left with the question of how much of this is already priced in. How do you view further growth, especially internationally, and any potential triggers going forward?·2 päivää sittenMedistim is still valued as a quality company, but the premium is not particularly high from a historical perspective. In my assessment, the valuation was more demanding in the period 2021 - 2023, while today's valuation is much more attractive. At a price around 215, you buy the share at approx. P/E 24.7, against historical averages of approximately 29.9 (3 years), 37.4 (5 years) and 37.5 (10 years). For that price, you get a company with: Gross margin: ~81.7% EBIT margin: ~28.0% Profit margin: ~22.8% FCF margin: ~22.2% ROE: ~34% ROIC: ~52% In addition, the company has a net cash position, good liquidity and a high equity ratio. Companies that consistently deliver these types of margins and capital returns are often valued at a premium. If Medistim continues to deliver at the same level regarding growth and profitability, the share can function well as a long-term compounder. And then one can speculate on what happens if they deliver even better, are acquired, or other triggering factors. But remember that the market knows this, so this is unfortunately no hidden gem. What can count positively is that the liquidity in the share is low and therefore prevents large players from actively trading it, as it takes time to get in and out with large positions. In my eyes, this can be a big and underestimated advantage if you are not going in and out with many millions every time. So then it's up to you to assess whether the company can continue to deliver and thus deserve the price you might be willing to pay for their cash flows.
- 18.3.18.3.Intertrade Shipping AS, which is partly owned and controlled by Øyvin A. Brøymer, has today purchased 50,000 shares in Medistim ASA at NOK 208 per share, - totaling NOK 10,400,000. Øyvin A. Brøymer is the chairman of the board in Medistim ASA. After the purchase, Intertrade Shipping AS owns 1,015,001 shares in the company. Fløtemarken AS, which is a 100% owned company of Intertrade Shipping AS, additionally owns 1,285,000 shares in Medistim ASA. In total, Øyvin A. Brøymer controls 2,300,001 shares in Medistim ASA after the purchased.
- 13.3.13.3.MEDI: Intertrade Shipping AS purchases Medistim shares Close i dag kl. 14:14 ∙ Oslo Børs Medistim Intertrade Shipping AS, which is partly-owned and controlled by Øyvin A. Brøymer, has today purchased 29,266 shares in Medistim ASA at NOK 200.5776 per share, - totaling NOK 5,875,974.14. Øyvin A. Brøymer is the chairman of the board in Medistim ASA. After the purchase, Intertrade Shipping AS owns 965,001 shares in the company. Fløtemarken AS, which is a 100% owned company of Intertrade Shipping AS, additionally owns 1,285,000 shares in Medistim ASA. In total, Øyvin A. Brøymer controls 2,250,001 shares in Medistim ASA after the purchase.
- ·13.3.I would like to know the reason for selling below 200 kr from some of those who are doing it now, after the company delivered stellar figures in Q4, a record year last year, and the highest dividend to date. I would appreciate hearing the reason for that, unless it's personal reasons, of course.
- ·12.3.This stock seems to be a somewhat forgotten stock. Very rarely mentioned in the financial press, and very little commented on in forums. This gem has been on the stock exchange for a long time, delivers good results with a record in Q4 and for the full year 2025. Quite decent dividend (8 kr /approx 4%) and an attractive portfolio of own products for hospitals and healthcare enterprises. This is not something AI can destroy, and this is also not a market that will cease to exist; on the contrary, healthcare will likely only grow due to an aging population. After the Q4 figures, it rose so much that I was tempted to sell out at 230, but have now bought back my shares again, at a price I find very favorable. No reason for Medistim to fall as it has done after the figures other than that it is an unsettled market. If one is long-term, one sits well in this fine stock, in my opinion.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt